# ClinicalTrials.gov record NCT02196831

> PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02196831-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02196831-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02196831-tesamorelin-v1.json
- Content SHA-256: `0a693d3b981009504503dc9d6ef4929fa675fb5ba99cf2513b9614c19d328d53`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02196831 ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

## Sources

<a id="source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5"></a>
- **ClinicalTrials.gov record NCT02196831 · retained source version 2020-01-27:6949b106f4e5a702e91a9ee7a8429948daad461514ce2523818c431f2e2e04c4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02196831) (`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02196831." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02196831-tesamorelin-v1.json SHA-256: 0a693d3b981009504503dc9d6ef4929fa675fb5ba99cf2513b9614c19d328d53.